Stocks of INVO Bioscience Inc [INVO] are gaining investors’ attention: here’s why

Stocks of INVO Bioscience Inc (NASDAQ:INVO) traded higher last session on Wall Street, up 22.90% to $1.61.

According to the data, INVO Bioscience Inc (NASDAQ:INVO) has 1 analysts covering its stock. The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $2.00 and a low of $2.00, we find $2.00. Given the previous closing price of $1.31, this indicates a potential upside of 52.67 percent. INVO stock price is now 56.62% away from the 50-day moving average and -71.99% away from the 200-day moving average. The market capitalization of the company currently stands at $3.98M.

Top 5 Artificial Intelligence Stocks to Buy for 2024

By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it. According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."

Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"


A total of 1 analysts have issued a hold rating and 0 have given it a buy rating. Brokers who have rated the stock have averaged $2.00 as their price target over the next twelve months.

A total of 0.94% of the company’s stock is owned by insiders.

Monday’s opening bell rang with an opening price of $1.3500 for INVO Bioscience Inc (NASDAQ: INVO). During the past 12 months, INVO Bioscience Inc has had a low of $0.50 and a high of $25.40. The fifty day moving average price for INVO is $1.0280 and a two-hundred day moving average price translates $5.7479 for the stock.

The latest earnings results from INVO Bioscience Inc (NASDAQ: INVO) was released for Jun, 2023. The net profit margin was -858.51% and return on equity was -1224.53% for INVO. The company reported revenue of $0.32 million for the quarter, compared to $0.15 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 116.44 percent.

INVO Bioscience Inc(INVO) Company Profile

INVO Bioscience, Inc., a commercial-stage fertility company, provides assisted reproductive technology solutions worldwide. Its flagship product is the INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman’s body. INVO Bioscience, Inc. was founded in 2007 and is based in Sarasota, Florida.

Related Posts